“These results are exciting because depression is common in Parkinson’s but we weren’t sure about the best way to treat it. Older antidepressants are effective but have a lot of side effects.
The newer antidepressants have fewer side effects but we didn’t know if they’d be effective in people with Parkinson’s. We were also worried that they might worsen the motor problems that come with the disease,” said research author Irene H. Richard, MD, of the University of Rochester Medical Center in New York and a member of the American Academy of Neurology.
Parkinson's disease is a chronic neurologic disorder that worsens over time, leaving patients less able to direct or control their movements due to the loss of cells in various parts of the brain. In addition to the physical problems, Parkinson’s can also cause psychological symptoms. Almost one-half of people with Parkinson’s suffer from depression, and it is a major cause of disability.
The drugs tested were paroxetine, which is an antidepressant in the class called selective serotonin reuptake inhibitors (SSRIs), and venlafaxine extended release, which is in the serotonin and norepinephrine reuptake inhibitors (SNRIs) class.
The clinical trial lasted three months and involved 115 people in various stages of Parkinson’s disease who met the criteria for depression. About one-third of the participants received paroxetine, one-third received venlafaxine and one-third received a dummy pill. The dosage of the drug could be increased until the participant’s depression was effectively treated.On average, the people receiving paroxetine had a 13 point (59 percent) improvement and those receiving venlafaxine had an 11 point (52 percent) improvement in their scores on the Hamilton Rating Scale for Depression. People who received the dummy pill had a 6.8 point (32 percent) improvement. The results, as measured by three other depression rating scales, were similar. “The study suggests that, while there is a clear ‘placebo’ effect, there is a greater benefit from the antidepressant medications,” said Richard.
The study was supported by the National Institutes of Health/National Institute of Neurological Disorders and Stroke and Johns Hopkins University School of Medicine. Wyeth Pharmaceuticals provided venlafaxine XR, while Glaxo-Smith Kline provided paroxetine.
The American Academy of Neurology, an association of 25,000 neurologists and neuroscience professionals, is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as stroke, Alzheimer’s disease, epilepsy, Parkinson’s disease and multiple sclerosis.
For more information about the American Academy of Neurology, visit http://www.aan.com
Rachel L. Seroka | American Academy of Neurology
Amputees can learn to control a robotic arm with their minds
28.11.2017 | University of Chicago Medical Center
The importance of biodiversity in forests could increase due to climate change
17.11.2017 | Deutsches Zentrum für integrative Biodiversitätsforschung (iDiv) Halle-Jena-Leipzig
MPQ scientists achieve long storage times for photonic quantum bits which break the lower bound for direct teleportation in a global quantum network.
Concerning the development of quantum memories for the realization of global quantum networks, scientists of the Quantum Dynamics Division led by Professor...
Researchers have developed a water cloaking concept based on electromagnetic forces that could eliminate an object's wake, greatly reducing its drag while...
Tiny pores at a cell's entryway act as miniature bouncers, letting in some electrically charged atoms--ions--but blocking others. Operating as exquisitely sensitive filters, these "ion channels" play a critical role in biological functions such as muscle contraction and the firing of brain cells.
To rapidly transport the right ions through the cell membrane, the tiny channels rely on a complex interplay between the ions and surrounding molecules,...
The miniaturization of the current technology of storage media is hindered by fundamental limits of quantum mechanics. A new approach consists in using so-called spin-crossover molecules as the smallest possible storage unit. Similar to normal hard drives, these special molecules can save information via their magnetic state. A research team from Kiel University has now managed to successfully place a new class of spin-crossover molecules onto a surface and to improve the molecule’s storage capacity. The storage density of conventional hard drives could therefore theoretically be increased by more than one hundred fold. The study has been published in the scientific journal Nano Letters.
Over the past few years, the building blocks of storage media have gotten ever smaller. But further miniaturization of the current technology is hindered by...
With innovative experiments, researchers at the Helmholtz-Zentrums Geesthacht and the Technical University Hamburg unravel why tiny metallic structures are extremely strong
Light-weight and simultaneously strong – porous metallic nanomaterials promise interesting applications as, for instance, for future aeroplanes with enhanced...
11.12.2017 | Event News
08.12.2017 | Event News
07.12.2017 | Event News
12.12.2017 | Physics and Astronomy
12.12.2017 | Earth Sciences
12.12.2017 | Power and Electrical Engineering